Prostatic Artery Embolization Using 100–300-μm Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up

PurposeTo report medium-term outcomes of prostatic artery embolization (PAE) using 100–300-μm trisacryl gelatin microspheres to treat lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH) and to evaluate how cone-beam computed tomography-measured prostate gland volume (PGV), median lobe enlargement (MLE), age, and Charlson Comorbidity Index (CCI) affect these results.Materials and MethodsSeventy-four consecutive patients who underwent PAE from April 2014 through August 2018 were retrospectively reviewed. Patients had International Prostate Symptom Score (IPSS) >12, Quality of Life (QoL) score >2, prostate gland volume (PGV) >40 mL, age older than 45 years, and medical therapy failure. Twelve patients were excluded for bladder pathology or prostate cancer. Patients (n = 62, age = 71.8 ± 9.3 years, CCI = 3.5 ± 1.7, PGV = 174 ± 110 mL) had pre-procedure IPSS = 22.4 ± 5.6, QoL score = 4.4 ± 0.9, and post-void residual (PVR) = 172 ± 144 mL. Post-procedure values were compared to baseline at 1, 3, 6, 12, and 24 months. Associations between outcomes and PGV, MLE, age, and CCI were evaluated. Adverse event recording used Clavien-Dindo classification.ResultsOne month after PAE (n = 37), IPSS improved to 7.6 ± 5.2 (P < .0001) and QoL score improved to 1.7 ± 1.4 (P < .0001). At 3 months (n = 32), improvements continued, with IPSS = 6.4 ± 5.1 (P < .0001), QoL score = 1.2 ± 1.2 (P < .0001), PVR = 53 ± 41 mL (P < .001), and PGV = 73 ± 38 mL (P < .0001). Results were sustained at 6 months (n = 35): IPSS = 6.4 ± 4.1 (P < .0001), QoL score = 1.2 ± 1.2 (P < .0001), PVR = 68 ± 80 mL (P < .0001), PGV = 60 ± 19 mL (P < .001). At 12 months, patients (n = 26) had IPSS = 7.3 ± 5.5 (P < .0001), QoL score = 1.2 ± 0.8 (P <.0001), PVR = 89 ± 117 mL (P < .0001), PGV = 60 ± 48 mL (P < .01). At 24 months, patients (n = 8) had IPSS = 8.0 ± 5.4 (P < .0001), QoL score = 0.7 ± 0.5 (P < .0001), PVR = 91 ± 99mL (P = 0.17), and PGV = 30 ± 5mL (P = .11). Improvements were independent of PGV, MLE, age, and CCI. Two grade II urinary infections occurred.ConclusionsPAE with 100–300-μm microspheres produced sustained substantial improvements in LUTS, PGV, and PVR, which were independent of baseline PGV, MLE, age, or CCI.     

四川省首例COVID-19婴儿病例分析及文献复习

目的探讨1例输入性、家庭聚集性严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的2^＋个月龄新型冠状病毒疾病(COVID-19)婴儿的临床流行病学资料及影像学资料特点，并进行文献复习。 方法选择2020年2月7日，四川省金堂县第一人民医院收治的2^＋个月龄COVID-19婴儿为研究对象。采用回顾性分析方法，收集该例婴儿的临床病例资料，对其临床流行病学特点、影像学资料、诊断、治疗方案及预后进行分析。本研究对报道COVID-19婴儿的相关文献进行复习，设定检索策略为：以"婴儿""新型冠状病毒肺炎""新型冠状病毒疾病""2019-nCoV""NCP""SARS-CoV-2""COVID-19""infant"等为关键词，在PubMed、Medline、中国知网、维普中文科技期刊数据库、万方数据知识服务平台，以及"医学界儿科频道"等公众平台及新闻网站中，检索相关文献，检索时间设定为2019年12月1日至2020年2月21日。总结符合本研究纳入、排除标准的文献中报道的COVID-19婴儿临床特点及其诊断、治疗方案与预后。本研究遵循的程序符合2013年修订的《世界医学协会赫尔辛基宣言》要求。 结果①病史采集、诊断、治疗结果：患儿，男性，生后2个月＋29 d；2020年1月18日，患儿姨妈自武汉返蓉，密切接触后，患儿出现气促、轻微咳嗽、腹泻等症状。入院后，患儿检查结果显示，肺炎支原体及衣原体、甲型及乙型流感病毒抗原均呈阴性。胸部CT检查结果显示，患儿双肺胸膜下多发性浅淡磨玻璃病灶。2次鼻咽拭子SARS-CoV-2核酸检测均呈阳性。根据流行病学史、临床与影像学表现及核酸检测结果，确诊为普通型COVID-19患儿。经过对症治疗后，患儿气促、咳嗽临床症状消失，胸部影像学检查结果显示，肺部炎症病灶吸收，SARS-CoV-2核酸检测呈阴性。目前，患儿继续观察中，等候出院。②文献复习结果：按照本研究设定的文献检索策略，共计检索出5篇国内有关婴儿COVID-19文献及2篇婴儿COVID-19新闻报道，涉及18例COVID-19婴儿的临床特点、诊断、治疗方案及预后等研究。这18例COVID-19婴儿，均具有家庭聚集性、输入性感染特点(武汉COVID-19患者接触史)。其中，3例新生儿及其母亲均为SARS-CoV-2感染者。出生后，对2例新生儿进行有效隔离，无感染者接触史。这18例COVID-19婴儿的首发症状为：发热5例(27.8%)、咳嗽及下呼吸道症状3例(16.7%)、打喷嚏及吐奶1例(5.6%)、无症状3例(16.7%)、病史不详6例(33.3%)。其中，7例婴儿文献报道胸部CT检查结果，并且均存在异常，表现为双肺或单侧肺纹理增粗、磨玻璃影和(或)实变影。除2例婴儿未报道预后情况外，其余16例婴儿均预后良好，无死亡病例报道。 结论文献报道的COVID-19婴儿及纳入本研究的1例婴儿，均具有输入性、家庭聚集性感染特点，而且对新生儿患者，目前尚不能排除母婴垂直传播可能性。对于临床症状相对较轻，肺部病变范围相对较小且局限的COVID-19婴儿，一般预后较好。在COVID-19暴发流行期，应尽可能加强儿童，特别是婴儿的防护，避免输入性、家庭聚集性SARS-CoV-2感染。     

消化道肿瘤完全植入式给药装置临床应用中国专家共识及操作指南（2019版）

完全植入式给药装置(totally implantable access port,以下简称PORT)是完全植入皮下并可长期留置的输液通道,可用于各种液体输注,包括化疗药物、肠外营养液和血液制品等。PORT具有护理简单、感染和栓塞风险低以及病人舒适度高等优势。根据不同输注路径,PORT包括静脉型^[1]、腹腔型^[2]和动脉型^[3]、鞘内型^[4],临床以静脉型PORT应用较为广泛。     

经皮肺穿刺肺癌兔应用化疗药物对肿瘤细胞沿针道转移率影响的研究

目的探究化疗药物对已进行经皮肺穿刺肺癌兔术后肿瘤细胞沿针道转移率的影响。方法将成功建立的肺癌兔模型分为治疗组24只,对照组20只,所有患兔在计算机断层扫描(CT)引导下成功进行细针吸取细胞学检查(FNAC)5次,治疗组在进行穿刺后保留套管拔出针芯,边给予化疗药物边撤出套管。沿针道搜集组织并进行病理细胞学检测。结果治疗组中,3个不同部位5次穿刺均未发现阳性转移的发生率比较,差异无统计学意义(P﹥0.05);对照组中,脏层胸膜5次穿刺均未发现阳性转移的发生率分别低于壁层胸膜和胸壁组织,差异均有统计学意义(P﹤0.05);治疗组脏层胸膜5次穿刺均未发现阳性转移的发生率高于对照组,差异有统计学意义(P﹤0.05)。穿刺后,治疗组脏层胸膜肿瘤细胞转移阳性率明显低于对照组,差异有统计学意义(P﹤0.01);两组壁层胸膜及胸壁组织的肿瘤细胞转移阳性率比较,差异均无统计学意义(P﹥0.05)。结论经皮肺穿刺肺癌兔使用化疗药物可降低肿瘤细胞沿针道的阳性转移率。     

Outcomes of vascular resection associated with curative intent hepatectomy for intrahepatic cholangiocarcinoma

Background and aimsWe aimed to investigate the impact of vascular resection (VR) on postoperative outcomes and survival of patients undergoing hepatectomy for intrahepatic cholangiocarcinoma (ICC).MethodsA retrospective analysis of a multi-institutional series of 270 patients with resected ICC was carried out. Patients were divided into three groups: portal vein VR (PVR), inferior vena cava VR (CVR) and no VR (NVR). Univariate and multivariate analysis were applied to define the impact of VR on postoperative outcomes and survival.ResultsThirty-one patients (11.5%) underwent VR: 15 (5.6%) to PVR and 16 (5.9%) to CVR. R0 resection rates were 73.6% in NVR, 73.3% of PVR and 68.8% in CVR. The postoperative mortality rate was increased in VR groups: 2.5% in NVR, 6.7% in PVR and 12.5% in CVR. The 5-years overall survival (OS) rates progressively decreased from 38.4% in NVR, to 30.1% in CVR and to 22.2% in PVR, p = 0.030. However, multivariable analysis did not confirm an association between VR and prognosis. The following prognostic factors were identified: size ≥50 mm, patterns of distribution of hepatic nodules (single, satellites or multifocal), lymph-node metastases (N1) and R1 resections. In the VR group the 5-years OS rate in patients without lymph-node metastases undergoing R0 resection (VRR0N0) was 44.4%, while in N1 patients undergoing R1 resection was 20% (p < 0.001).ConclusionVascular resection (PVR and CVR) is associated with higher operative risk, but seems to be justified by the good survival results, especially in patients without other negative prognostic factors (R0N0 resections).     

盐酸氨溴索治疗小儿支气管肺炎的临床分析

目的分析研究盐酸氨溴索用于小儿支气管肺炎的临床效果。方法将本院2017年12月—2018年12月期间收治的小儿支气管肺炎患儿88例按照随机双盲法均分为对照组和治疗组,予以对照组44例患儿常规治疗,予以治疗组44例患儿常规治疗联合氧气驱动雾化吸入盐酸氨溴索治疗,对两组患儿的临床疗效和临床症状缓解时间进行对比。结果与对照组相比,治疗组患儿咳嗽、咳痰、胸片改善时间及肺部干湿啰音缓解时间均显著短于对照组,组间差异具有统计学意义(P<0.05),治疗组的临床总有效率为95.45%(42/44),明显高于对照组77.27%(34/44),组间差异具有统计学意义(P<0.05)。结论小儿支气管肺炎在临床常规治疗的基础上加用盐酸氨溴索治疗有助于患儿临床症状的缓解,效果明显。